RESPIRATORY SYNCYTIAL VIRUS- HEALTHCARE RESOURCE UTILIZATION IN BRAZILIAN CHILDREN <5 YEARS: SURVEILLANCE AND HOSPITAL DATA, 2022-2024
Author(s)
Ana Luiza Bierrembach, PhD1, Cassia Veiga, PhD2, Erick Kazu, PhD1, Liza Uchimura, PhD1, Mariana Rosim, PhD2, Felype Castelhano, BSc2, Vinicius Goularte-Silva, PhD1, Cintia Parellada, PhD2.
1Precision Data, São Paulo, Brazil, 2MSD Brazil, São Paulo, Brazil.
1Precision Data, São Paulo, Brazil, 2MSD Brazil, São Paulo, Brazil.
OBJECTIVES: To describe HCRU associated with RSV-specific hospitalizations among children aged <5 years in Brazil between 2022 and 2024.
METHODS: A retrospective descriptive analysis was conducted using two national data sources in Brazil to assess HCRU in hospitalized children aged < 5 years. Cases were identified in the Epidemiological Surveillance Information System (SIVEP) and in the hospital-based administrative data system (SIH) using International Classification of Diseases, 10th Revision (ICD-10), RSV-specific codes. Outcomes included median length of stay (LOS), intensive care unit (ICU) utilization, and in-hospital case fatality rate (CFR) stratified by age group.
RESULTS: Between 2022 and 2024, 62,708 RSV-specific hospitalizations were identified in SIH and 71,229 in SIVEP. Infants aged <6 months accounted for most RSV hospitalizations (62.9% in SIH and 53.6% in SIVEP), followed by children aged 6-11 months (20.8-22.1%), 12-23 months (10.7-14.3%), and 24-59 months (5.5-10%). In SIH, the median LOS was 4 days (IQR 2-6), with ICU admission in 11.9% of the hospitalizations. ICU admission was highest among neonates <1 month (21.6%) and infants aged 1-5 months (13.8%), decreasing progressively with age. In SIVEP, the LOS was highest among neonates aged <1 month (8 days; IQR 5-12) and infants aged 1-5 months (7 days; IQR 4-11), compared with 5 days (IQR 3-7) among those aged 24-59 months. CFR was 1.2% and remained relatively consistent across age groups.
CONCLUSIONS: Although concentrated in infants aged <6 months, RSV caused clinically significant disease across all pediatric ages. Long LOS, ICU use, and non-negligible CFR highlight a substantial inpatient burden of RSV in Brazilian children aged <5 years and support early life prevention.
METHODS: A retrospective descriptive analysis was conducted using two national data sources in Brazil to assess HCRU in hospitalized children aged < 5 years. Cases were identified in the Epidemiological Surveillance Information System (SIVEP) and in the hospital-based administrative data system (SIH) using International Classification of Diseases, 10th Revision (ICD-10), RSV-specific codes. Outcomes included median length of stay (LOS), intensive care unit (ICU) utilization, and in-hospital case fatality rate (CFR) stratified by age group.
RESULTS: Between 2022 and 2024, 62,708 RSV-specific hospitalizations were identified in SIH and 71,229 in SIVEP. Infants aged <6 months accounted for most RSV hospitalizations (62.9% in SIH and 53.6% in SIVEP), followed by children aged 6-11 months (20.8-22.1%), 12-23 months (10.7-14.3%), and 24-59 months (5.5-10%). In SIH, the median LOS was 4 days (IQR 2-6), with ICU admission in 11.9% of the hospitalizations. ICU admission was highest among neonates <1 month (21.6%) and infants aged 1-5 months (13.8%), decreasing progressively with age. In SIVEP, the LOS was highest among neonates aged <1 month (8 days; IQR 5-12) and infants aged 1-5 months (7 days; IQR 4-11), compared with 5 days (IQR 3-7) among those aged 24-59 months. CFR was 1.2% and remained relatively consistent across age groups.
CONCLUSIONS: Although concentrated in infants aged <6 months, RSV caused clinically significant disease across all pediatric ages. Long LOS, ICU use, and non-negligible CFR highlight a substantial inpatient burden of RSV in Brazilian children aged <5 years and support early life prevention.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EPH250
Topic
Epidemiology & Public Health
Topic Subcategory
Public Health
Disease
Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory)